My research is focused on the best ways to use genetic information to improve outcomes of patients with or at risk for hereditary cancers of all types. This includes the integration of genetic testing for both common and rare variants into clinical management, as well as evaluation of the clinical usefulness of genome-wide association studies.
I have played an active role in investigating and assessing cancer risks associated with BRCA mutations, especially those associated with breast and ovarian cancer, and conducting studies to define the clinical behavior and optimal management of individuals carrying BRCA mutations.
I also participate in the development of new treatments, such as PARP inhibitors, which may be particularly useful in people with BRCA mutations.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Mark E. Robson discloses the following relationships and financial interests:
-
Artios Pharma Limited
Professional Services and Activities (Uncompensated) -
AstraZeneca
Professional Services and Activities (Uncompensated) -
Change Healthcare Inc.
Professional Services and Activities -
Clinical Care Options
Professional Services and Activities -
Foundation Medicine
Professional Services and Activities (Uncompensated)
-
Genome Quebec
Professional Services and Activities -
myMedEd, Inc.
Professional Services and Activities -
Pfizer, Inc.
Professional Services and Activities (Uncompensated) -
WebMD
Professional Services and Activities
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].
View all disclosures